Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration

NCT04746963 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped Adverse Events

Conditions

Neovascular Age-Related Macular Degeneration (nAMD)

Interventions

DRUG: AXT107 0.1 mg
DRUG: AXT107 0.25 mg
DRUG: AXT107 0.5 mg

Sponsor

AsclepiX Therapeutics, Inc.